These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
211 related items for PubMed ID: 11926567
1. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. Frazzoni M, Grisendi A, Lanzani A, Melotti G, De Micheli E. Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567 [Abstract] [Full Text] [Related]
3. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076 [Abstract] [Full Text] [Related]
4. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. Newton M, Burnham WR, Kamm MA. Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269 [Abstract] [Full Text] [Related]
5. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, Cucchiara S. Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573 [Abstract] [Full Text] [Related]
6. The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. Wetscher GJ, Glaser K, Gadenstaetter M, Profanter C, Hinder RA. Am J Surg; 1999 Mar; 177(3):189-92. PubMed ID: 10219852 [Abstract] [Full Text] [Related]
7. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. Wong WM, Lai KC, Hui WM, Lam KF, Huang JQ, Hu WH, Wong NY, Lam CL, Xia HH, Chan AO, Lam SK, Wong BC. Aliment Pharmacol Ther; 2004 Feb 15; 19(4):455-62. PubMed ID: 14871286 [Abstract] [Full Text] [Related]
8. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Aliment Pharmacol Ther; 2002 May 15; 16(5):881-6. PubMed ID: 11966495 [Abstract] [Full Text] [Related]
9. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Katz PO, Anderson C, Khoury R, Castell DO. Aliment Pharmacol Ther; 1998 Dec 15; 12(12):1231-4. PubMed ID: 9882031 [Abstract] [Full Text] [Related]
10. Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up. Mehta S, Bennett J, Mahon D, Rhodes M. J Gastrointest Surg; 2006 Nov 15; 10(9):1312-6; discussion 1316-7. PubMed ID: 17114017 [Abstract] [Full Text] [Related]
11. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. Viljakka M, Nevalainen J, Isolauri J. Scand J Gastroenterol; 1997 Aug 15; 32(8):766-72. PubMed ID: 9282967 [Abstract] [Full Text] [Related]
12. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Jaspersen D, Diehl KL, Schoeppner H, Geyer P, Martens E. Aliment Pharmacol Ther; 1998 Jan 15; 12(1):49-52. PubMed ID: 9692700 [Abstract] [Full Text] [Related]
13. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Nzeako UC, Murray JA. Aliment Pharmacol Ther; 2002 Jul 15; 16(7):1309-16. PubMed ID: 12144581 [Abstract] [Full Text] [Related]
14. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. Gardner JD, Sloan S, Robinson M, Miner PB. Aliment Pharmacol Ther; 2003 Jul 01; 18(1):133-40. PubMed ID: 12848635 [Abstract] [Full Text] [Related]
15. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. Bautista J, Fullerton H, Briseno M, Cui H, Fass R. Aliment Pharmacol Ther; 2004 May 15; 19(10):1123-30. PubMed ID: 15142202 [Abstract] [Full Text] [Related]
16. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Xia HH, Lai KC, Lam SK, Hu WH, Wong NY, Hui WM, Lau CP, Chen WH, Chan CK, Wong WM, Wong BC. Aliment Pharmacol Ther; 2003 Feb 15; 17(3):369-77. PubMed ID: 12562449 [Abstract] [Full Text] [Related]
17. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Aliment Pharmacol Ther; 2003 Jan 15; 17(2):235-41. PubMed ID: 12534408 [Abstract] [Full Text] [Related]
19. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Garg SK, Gurusamy KS. Cochrane Database Syst Rev; 2015 Nov 05; 2015(11):CD003243. PubMed ID: 26544951 [Abstract] [Full Text] [Related]
20. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Arch Intern Med; 2000 Jun 26; 160(12):1803-9. PubMed ID: 10871974 [Abstract] [Full Text] [Related] Page: [Next] [New Search]